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In recent years, GPCR targets from diverse regions of phylogenetic space have been determined. This
effort has culminated this year in the determination of representatives of all major classes of GPCRs
(A, B, C, and F). Although much of the now well established knowledge on GPCR structures has been
known for some years, the new high-resolution structures allow structural insight into the causes of
ligand efﬁcacy, biased signaling, and allosteric modulation. In this digest the structural basis for GPCR sig-
naling in the light of the new structures is reviewed and the use of the new non-class A GPCRs for drug
design is discussed.
 2014 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Cellular signal transduction pathways are canonical points for
drug interaction, where whole downstream signaling cascades
can be manipulated by interfering with a single target. Signal
transduction interfaces between two compartments, such as the
cell exterior and interior, provide an especially well suited point
for signal regulation due to the spatial separation of ligand interac-
tion site and effect. With about 850 members G-protein coupled
receptors (GPCRs) form the largest human superfamily of recep-
tors,1 being responsible for signal transduction from the cytosol
to the cell interior. Out of this number about 350 receptors are
potentially druggable2 although for about 100 so called orphan
receptors3 neither the endogenous ligand nor the physiological
function is yet known. The opportunity to have a molecular switch
at hand, which triggers a signaling cascade in the cell interior, and
in addition the heterogeneous distribution of GPCRs in different
tissues, makes them a highly interesting pharmaceutical class of
targets.4 It has been estimated, that about 50% of all modern drugs
act on GPCRs. Thereby documenting that this class of receptors has
been a successful target for the pharmaceutical industry.5
As their function implicates, GPCRs are transmembrane pro-
teins, which makes structure elucidation much more difﬁcult than
for globular proteins. Until the structure of bovine rhodopsin was
solved6 in 2000 no X-ray structure of any GPCR was available.
Although being a huge step forward in terms of structural under-
standing of GPCRs, the rhodopsin structure itself was only of lim-
ited help for conventional drug design on pharmaceutically more
relevant GPCRs. It took more than seven years until b2 and b1
adrenergic receptors (b2R and b1R) were solved employing newreceptor stabilization and crystallization techniques,7–9 opening
the door to a strongly accelerated elucidation frequency of new
receptors. To date (June 2014) X-ray structures of 20 different class
A, two class B, one class C, and one frizzled GPCR, spanning large
sections of the phylogenetic tree, have been published.10 This
now gives pharmaceutical researchers the opportunity to use these
structures for drug design purposes. Most especially, the very
recent structures of non-class A GPCRs may serve as invaluable
templates for ligand design for these very difﬁcult target classes.
Although both classes are attractive drug target families, very
few small molecule drugs targeting class B or C GPCRs are on the
market. This reﬂects the impact of their apparently highly demand-
ing binding sites, in terms of druggability. For class A receptors
some structures with approved drugs are available. These include
the complexes of: maraviroc in CCR5, tiotropium in M3 receptor,
adenosine in A2A receptor (A2AR), carvedilol in b1R, doxepin in
H1 receptor (H1R), ergotamine in 5-HT1B as well as 5-HT2B recep-
tors, and voraxapar in the protease-activated receptor PAR-1. In
addition to the new X-ray structures from classes B and C, a ﬁrst
structure of an agonist bound M2 receptor structure with allosteric
modulator as well as two very high-resolution structures of A2AR
and d-opioid receptors (d-OR) were recently reported, providing
ﬁrst insight into the allosteric regulation, biased signaling and sol-
vent networks in GPCRs. These recent advances and their implica-
tion for drug design will be discussed in the following sections.
Several recent reviews cover the use of GPCR structures in
structure based drug design. For a non-exhaustive list please see
references 11–13. Structure based drug design for GPCRs is cur-
rently in most cases limited to virtual screening14 or to modeling
a ligand of interest into a public domain X-ray structure of a GPCR
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tal structures with the compound of interest are generated. These
studies correspond to the most preferred scenario for ligand opti-
mization, because no uncertainties regarding the ligand binding
pose and induced ﬁt effects are envisioned. One of the few reported
studies is the structure guided optimization of A2AR antagonists
reported by Congreve et al.15 In that study compounds discovered
by virtual screening were optimized by use of their corresponding
X-ray structures. At this time, most pharmaceutical companies do
not have the facilities to crystallize GPCRs, therefore the emphasis
of this digest will be on the use of public domain structures for
drug design.
Insight from high-resolution structures: Recently the structures of
A2AR and d-OR16,17 have been solved with a resolution of less than
2 Å. Although X-ray structures of both receptors have been
reported before, only very high-resolution structures clarify the
location of solvent molecules, as well the binding site of sodium
ions. Although the two receptors stem from completely different
subfamilies of GPCRs, the internal water network and sodium bind-
ing site are highly conserved. The metal binding site involves some
of the known conserved motifs of class A GPCRs (such as the NPxxY
motif on TM7, the WxP motif on TM6 as well as the N2.50 motif on
TM2—TM stands for transmembrane helix), as shown in the over-
lay of the structures in Figure 1.
The current understanding is that sodium is an allosteric mod-
ulator of GPCRs18 inﬂuencing the ability of b-arresting signaling, as
discussed in the next chapter. The water network connecting the
ligand binding site with the intracellular interface is very much
conserved in the two high-resolution structures. In addition, also
many other GPCR X-ray structures show a direct involvement of
water molecules in ligand binding to the receptor. For example
in A2AR, b1R, CXCR4, d-OR, j-OR, PAR-1, and sphingosine-1-phos-Figure 1. Overlay of the two available very high-resolution GPCR structures of A2AR (ora
the conserved sodium (green spheres) binding site involves three of the well-known co
pocket of both ligands, mediating ligand interactions with the receptor. (The residue numphate receptor 1 (S1P1) X-ray structures show water mediated
ligand contacts to the receptor.13 The high degree of involvement
of water molecules in GPCR ligand binding makes rational ligand
design without corresponding X-ray structure very difﬁcult. This
is because the structure activity relationships are greatly changed
when a bridging water entity is replaced. The knowledge that
water location is crucial in GPCRs has led to studies which explic-
itly investigate the thermodynamic properties of water molecules
in GPCR X-ray structures to answer the question: Can speciﬁc
water molecules can be replaced by ligand atoms?19
Ligand bias: In recent years, the awareness of the importance of
different signaling capabilities of various ligands through GPCRs
has steadily grown. One GPCR can signal throughmultiple different
downstream pathways. Beyond the name-giving signaling through
G-proteins, signaling through b-arrestin or direct signaling through
receptor associated kinases is known20,21 Ligands can activate
different signaling pathways to differing extents (‘ligand biased
signaling’), where current insight suggests that the different path-
ways are decoupled.22 The understanding of the consequences of
different signaling behavior is crucial for drug design, especially
as it has been assumed that ligand bias can be exploited to design
superior next-generation drugs, for example, for heart failure23 or
antipsychotics.24
Although the different signaling pathways have been known for
some time, ligand features or receptor behavior leading to signal-
ing-biased receptor states have not been fully elucidated. The cur-
rent understanding of the differences of G-protein and b-arrestin
signaling is that activation of either pathway results from different
conformational changes to the receptor.22 The signaling through G-
proteins works via association of a GTP-loaded G-protein at the
TM3–TM5–TM6 interface of the respective GPCR, while b-arrestin
is proposed to dock at the spatially distinct TM1–TM2–TM7nge, PDB code: 4EIY) and d-OR (cyan, PDB code: 4N6H). The water network around
nserved motifs in class A GPCRs. A large water network is also seen in the binding
bering corresponds to the Weinstein-Ballesteros nomenclature for class A GPCRs.)
Figure 2. (A) structures of carazolol (inverse agonist) and carvedilol (biased ligand, agonist for b-arrestin, antagonist for G-protein pathway). (B) Extracellular view of the
overlay of X-ray structures of b1 bound with carazolol (red, 2YCW) and carvedilol (green, 4AMJ). The biased ligand carvedilol (dark green) induces a signiﬁcantly increased
distance (2 Å) between TM2 and TM7.
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question is the interaction of biased ligands with the respective
receptors. For class A receptors it has been shown that ligands
which activate the G-protein pathway trigger the conformational
switch of two interacting side chains on TM3 (3.40) and TM6
(6.44) just below the generic binding site.25 This results in a
straightening of TM3, a kinking of TM6 and the opening of the G-
protein binding site at the intracellular surface of the receptor.
For b-arrestin signaling no b-arrestin bound activated structures
are available yet, but the collected evidence points towards the
involvement of the TM1–TM2–TM7 water network/sodium bind-Figure 3. Overlay of the class B structures (CRF1R ining site in the activation process. Disrupting the sodium network
in d-OR induces high levels of constitutive activity in b-arrestin sig-
naling, while completely shutting down basal G-protein signal-
ing.16 Interaction of the ligand with TM7 is postulated to
modulate b-arrestin signaling.22 Structures of b1R with biased
ligands support this view,26 as some small structural variations
in ligand binding are seen close to TM2 and TM7. A supportive
example for the ability to modulate the signaling efﬁcacy of b1R
ligands is shown in Figure 2. The size extension of the inverse ago-
nist carazolol towards TM7 results in carvedilol, which is an antag-
onist for G-protein signaling, but an agonist for the b-arrestingold and GCGR in cyan) with b2R (2RH1 in red).
4076 C. S. Tautermann / Bioorg. Med. Chem. Lett. 24 (2014) 4073–4079pathway.27 The overlay of the b1R crystal structures bound to these
two ligands shows distinct differences in the position of TM2 and
TM7. This example shows how ligand bias can be introduced by
quite simple chemical modiﬁcations. To investigate the problem
from a receptor point of view, the two serotonin receptors 5-
HT1B and 5-HT2B have been crystallized both with the same ligand
bound.28,29 Ergotamine is a ‘conventional’ full agonist on the 5-
HT1B receptor, activating both signaling pathways, but it is a biased
agonist on the 5-HT2B receptor strongly favoring the b-arrestin
pathway. Comparison of the structures conﬁrms the current
hypothesis of the conformational switch of residues 3.40 and
6.44 for G-protein activation and a conformational change in
TM7 for b-arrestin activation.28
However, it is currently not possible to predict the efﬁcacy of
ligands a priori,30 therefore only compound synthesis and biologi-
cal testing will deﬁnitely shed light on the actual signaling behav-
ior of each ligand. Several examples have now shown that very
minor modiﬁcations can turn antagonists into activators,31 even
allowing antagonist design starting from known agonists.32 To
wrap up, through the latest class A GPCR structures a deeper
understanding of GPCR activation and biased signaling has been
achieved, giving medicinal chemists ideas to develop SAR in either
pathway direction. The prerequisite for biased drug discovery is a
clear biological rationale about which pathway of a GPCR has to
be (de)activated in order to gain the optimal effect in the targeted
disease.33
Class B and class C GPCRs: Since the solution of b2 in 20079
nearly 20 different class A GPCRs in various activation states have
been solved before the ﬁrst non-class A structures emerged with
the smoothened receptor (class F),34 glucagon receptor (GCGR,
class B),35 the corticotropin releasing factor 1 receptor (CRF1R,Figure 4. Distribution of molecular weight and c logP for all compounds reported to be ac
that ligands for GCGR are heavy and lipophilic, ligands for CRF1R are medium sized
lipophilicity is fairly high. As examples for druggable targets the distributions for A2ARclass B),36 and very recently the metabotropic glutamate receptor
1 (mGluR1, class C).37 Receptors from these classes are very attrac-
tive drug-targets, but it has proven to be very hard to ﬁnd small
molecule drugs which can make it to the market. For class B, the
secretin receptors, only peptide drugs are on the market, although
strong efforts were directed in ﬁnding small molecules.38 The
endogenous ligands for class B GPCRs are mid-size peptide hor-
mones, interacting with the GPCR over a large protein-protein
interaction surface. Finding drugs to interrupt such interactions
often proves to be quite demanding, especially the identiﬁcation
of the actual interaction site of the ligand with the receptor is hard
to determine without X-ray crystallography. For class C with bac-
lofen (competitively targeting the GABAB receptor) and cinacalcet
(allosterically targeting the calcium sensing receptor) two drugs
are registered, however for the family of metabotropic glutamate
receptors no drugs are approved so far, although these targets
are identiﬁed as highly rewarding drug targets for allosteric
modulation.39
Class B. Although the non-class A GPCRs do not share the well-
known conserved class A motifs, the overall fold and the interheli-
cal interaction networks are strongly conserved.38 TM helices 1–5
of the solved class B receptors are in better structural agreement
with the class A counterparts than TMs 6 and 7. The largest differ-
ence of class B structures in comparison to class A is the very deep
and open V-shaped crevice. Figure 3 shows a comparison of a pro-
totypical class A receptor (b2R) with the two class B receptors.
In addition to the larger crevice, the location of the antagonist
binding site in CRF1R is very surprising, being much deeper buried
in the helical bundle than in all known class A cases (shifted more
than 10 Å further towards the cytosol). As already mentioned, the
arrangements of the transmembrane helices is well conservedtive in ChEMBL for A2AR, H1R, GCGR, CRF1R, and mGluR1. The overall pictures shows
but also very lipophilic. Also ligands for mGluR1 are generally small in size, the
and H1R reveal low lipophilicity and a large fraction of small ligands.
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deviations, also within class B structures. Within CRF1R these heli-
ces are positioned much further away from the center of the helical
bundle, where TM6 has a different tilt and TM7 shows a strong out-
ward kink compared to GCGR. It is speculated that this difference
may be the consequence of ligand binding, because CRF1R has been
solved with a small molecule antagonist bound, whereas in GCGR
the ligand density could not be recovered. Therefore, the binding
crevice of CRF1R is the largest one in all GPCRs solved so far. In
depth investigation of class B binding sites reveals they have a
low druggability38 characterized by an open pocket which is
mostly ﬁlled with bulk-like water and the presence of only one
hot spot residue. In this respect the class B pockets are similar to
the CXCR4 small molecule ligand binding site. With the low drug-
gability in mind, it is not surprising that no small molecule drugs
are marketed for class B GPCRs.
Examination of all published GCGR and CFR1R active ligands
from ChEMBL,40 reveals that their calculated physicochemical
properties are predominantly in an unfavorable region. This is
anticipated to cause safety problems and unacceptable PK proper-
ties, as is also reported in the literature.41 Druggable targets, such
as H1R or A2AR, show a completely different proﬁle for their
ligands with low molecular weight and low c logP distributions,
as shown in Figure 4. The optimization of initial screening hits or
lead classes is much more demanding for heavy and/or lipophilic
compounds as found for class B receptors. All these reasons make
the ﬁrst class B X-ray structures invaluable tools for medicinal
chemists because they may enable structure based drug design
efforts. With these structures, and homology models derived there-
from, a focused effort to reduce the ligand’s liabilities can be
guided by in silico modeling support. To demonstrate the usability
of the CRF1R structure we take the ligand conformation from theFigure 5. When superposing CRF1R active compounds from ChEMBL with the bioactiv
neatly ﬁts into the receptor binding site.X-ray structure and overlay it with the 300 currently (status April
14) most potent ligands (potency range 0.2–3 nM) reported in
ChEMBL40 coming from 49 different publications. The ligand based
superposition is done in a purely automated fashion42 and the
result is scientiﬁcally not actually surprising, but striking—the
overall shape of the set of ligands matches exactly the shape of
the binding pocket (see Fig. 5), although various core modiﬁcations
(bicyclic cores) are observed. Thus, all highly potent compounds
are apparently binding to the same binding pocket in a similar ori-
entation. This means in turn that the availability of the X-ray struc-
ture early on would have triggered much more focused exploration
of the lead classes leading to a faster progression during optimiza-
tion and probably more drug-like compounds.
For GCGR the small molecule antagonist cannot be found in the
X-ray structure, and no obvious binding mode can be proposed.
However, with a large set of single point mutagenesis experiments
at least a conclusive binding hypothesis for glucagon could be
established.36 The direct use of this structure for drug design will
not be straightforward, but rather some modeling steps will be
needed for a proper description of a lead class binding mode. Pow-
erful techniques, such as molecular dynamics simulations, which
are currently applied to GPCRs on a regular basis,43 will help to
investigate the dynamics of the receptors and to look for induced
binding pockets.
Class C. Class C has been the last class of GPCRs to be elucidated
by X-ray crystallography. Very recently the heptahelical trans-
membrane region (abbreviated as 7-TM region) of mGluR1 bound
to a negative allosteric modulator (NAM) has been reported.37
Class C is highly relevant for drug design because class C receptors
play important roles in synaptic transmission and calcium homeo-
stasis, comprising the metabotropic glutamate receptors (mGluRs),
the c-aminobutyric acid B receptors (GABAB), the calcium sensinge conformation retrieved from the CRFR1 X-ray structure, the resulting ligand set
Figure 6. X-ray structure of mGluR1 bound to a negative allosteric modulator
(gold). b2R bound to carazolol is shown as overlay (red). The ligand binding sites
overlap strongly.
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large N-terminal domain (the so-called venus ﬂytrap domain)
which is the recognition site for the small endogenous agonists,
such as glutamate, GABA or Ca2+. Upon agonist binding in the N-
terminal region, the 7-TM-bundle undergoes conformational
change by a currently unknown mechanism. This eventually
enables G-protein association, involving a cysteine-rich domain,
which links the venus-ﬂytrap domain with the 7-TM-domain of
the receptor. Due to the highly conserved nature of the orthosteric
binding site of the individual class C subclasses, drug selectivity
can essentially only be achieved by allosteric modulation. There
is a long history for the development of allosteric modulators of
class C receptors and eventually most modulators have been
shown to bind in the 7-TM-region, close to the generic binding site
in class A receptors.44 However, for the mGluRs and GABAB recep-
tors currently no marketed small molecule allosteric modulator is
available, although these receptors have been identiﬁed as very
attractive drug targets for CNS disorders.45 The known ligands for
mGluRs are mostly linear, ﬂat and often quite small, but hydropho-
bic molecules (see Fig. 4) with non drug-like properties. In addition
to that, often only very subtle structural differentiation between
molecules working as positive or negative allosteric modulators
(PAMs or NAMs) are found.46 Small structural changes can convert
NAMs into PAMs or even SAMs, which stands for ‘silent allosteric
modulator’ and is a binding ligand, which acts functionally neu-
tral.47 In return small changes in mGluRs binding sites, introduced
by single point mutations, can invert the efﬁcacy of ligands.48 To
understand these decisive differences, structurally knowledge of
the allosteric binding site is essential.
The X-ray structure of the mGluR1 receptor37 conﬁrms the
hypothesis that the class C allosteric binding site is overlapping
with the class A generic (or orthosteric) small molecule binding
site. The accessibility to the binding site is obstructed by loop
regions, and only a very narrow entry channel to the receptor is
visible in the structure, as shown in Figure 6. This receptor pecu-
liarity as well as the topology of the binding site itself explains
the preference for mostly small, linear and ﬂat ligands by mGluR1.
The binding site is lipophilic and restricted in size, corresponding
to the ligand weight and c logP distribution shown in Figure 4.
The large hope is that this structure will help now to guide lead
optimization campaigns to yield drugs that are more successful.
However, due to the quite featureless mGluR1 binding site, in silico
approaches for ligand placement, such as ligand docking, are very
challenging. Especially, the subtle dependence of ligand efﬁcacy
on small structural changes requires a very accurate binding mode
prediction to be of use for compound optimization. It remains to be
clariﬁed if the structural differences between NAM and PAM bound
class C GPCRs are somehow related to the differences between ago-
nist and inverse agonist binding in class A receptors. Beyond that, it
is not known how the venus ﬂytrap domain communicates with
the TM region and why these receptors only work as covalently
linked dimers. All these additional layers of complexity render
the class C receptors currently to the least understood class of
GPCRs. However, the solution of the ﬁrst class C GPCR structure
was one of the major milestones for a proper understanding of
class C structure and function.
Conclusions: The recent solution of class B and C GPCRs struc-
tures as well as very high-resolution structures of two class A
GPCRs has opened new views on GPCR structure and function.
The difference between G-protein and b-arrestin signaling can to
some extent be explained by interpretation of the corresponding
X-ray structures. It is now only a matter of time until the ﬁrst
b-arrestin bound GPCR will be solved to test the validity of the cur-
rent view. This understanding is extremely important, but the
application to biased ligand design is not straightforward, as long
as we are at the stage of explaining rather than predicting effects.The structures from class B and C are milestones. However the
use of these structures in drug design is also not straightforward
because the ligand binding sites are either very large, or very lipo-
philic, thus being of low druggability. For class B ligand binding
may lead to strong induced structural changes, however the ligand
is not seen in all class B receptor X-ray structures. Still, the said
structures are invaluable tools for the interpretation of ligand
SAR, and with the combination of modeling efforts, supported by
mutagenesis information, these structures will prove to be power-
ful tools in lead optimization programs.
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